Literature DB >> 23473290

Mycobacterium leprae is identified in the oral mucosa from paucibacillary and multibacillary leprosy patients.

M A M Morgado de Abreu1, A M Roselino, M Enokihara, S Nonogaki, L E Prestes-Carneiro, L L M Weckx, M M A Alchorne.   

Abstract

In leprosy, the nasal mucosa is considered as the principal route of transmission for the bacillus Mycobacterium leprae. The objective of this study was to identify M. leprae in the oral mucosa of 50 untreated leprosy patients, including 21 paucibacillary (PB) and 29 multibacillary (MB) patients, using immunohistochemistry (IHC), with antibodies against bacillus Calmette-Guérin (BCG) and phenolic glycolipid antigen-1 (PGL-1), and polymerase chain reaction (PCR), with MntH-specific primers for M. leprae, and to compare the results. The material was represented by 163 paraffin blocks containing biopsy samples obtained from clinically normal sites (including the tongue, buccal mucosa and soft palate) and visible lesions anywhere in the oral mucosa. All patients and 158 available samples were included for IHC study. Among the 161 available samples for PCR, 110 had viable DNA. There was viable DNA in at least one area of the oral mucosa for 47 patients. M. leprae was detected in 70% and 78% of patients using IHC and PCR, respectively, and in 94% of the patients by at least one of the two diagnostic methods. There were no differences in detection of M. leprae between MB and PB patients. Similar results were obtained using anti-BCG and anti-PGL-1 antibodies, and immunoreactivity occurred predominantly on free-living bacteria on the epithelial surface, with a predilection for the tongue. Conversely, there was no area of predilection according to the PCR results. M. leprae is present in the oral mucosa at a high frequency, implicating this site as a potential means of leprosy transmission.
© 2013 The Authors Clinical Microbiology and Infection © 2013 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Keywords:  Epidemiology; Mycobacterium leprae; immunohistochemistry; leprosy; oral mucosa; polymerase chain reaction

Mesh:

Substances:

Year:  2013        PMID: 23473290     DOI: 10.1111/1469-0691.12190

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  6 in total

1.  Final diagnosis of 86 cases included in differential diagnosis of American tegumentary leishmaniasis in a Brazilian sample: a retrospective cross-sectional study.

Authors:  Fernanda Tirelli; Sebastian Vernal; Ana Maria Roselino
Journal:  An Bras Dermatol       Date:  2017 Sep-Oct       Impact factor: 1.896

2.  Mycobacterium leprae on Palatine Tonsils and Adenoids of Asymptomatic Patients, Brazil.

Authors:  Marilda Aparecida Milanez Morgado de Abreu; Gisele Alborghetti Nai; Juliana D'Andrea Molina; Rafael Tomaz Gomes; Natalia de Paula; Ana Maria Roselino
Journal:  Emerg Infect Dis       Date:  2020-10       Impact factor: 6.883

3.  Clinical and radiological evaluation of maxillofacial and otorhinolaryngological manifestations of Hansen's disease.

Authors:  Rachel Bertolani do Espírito Santo; Rachel Azevedo Serafim; Rafael Maffei Loureiro; Dâmaris Versiani Caldeira Gonçalves; Daniel Vaccaro Sumi; Ricardo Andrade Fernandes de Mello; Simon M Collin; Patrícia D Deps
Journal:  Sci Rep       Date:  2022-09-01       Impact factor: 4.996

Review 4.  PCR-based techniques for leprosy diagnosis: from the laboratory to the clinic.

Authors:  Alejandra Nóbrega Martinez; Carolina Talhari; Milton Ozório Moraes; Sinésio Talhari
Journal:  PLoS Negl Trop Dis       Date:  2014-04-10

5.  Leprosy: a review of laboratory and therapeutic aspects--part 2.

Authors:  Joel Carlos Lastória; Marilda Aparecida Milanez Morgado de Abreu
Journal:  An Bras Dermatol       Date:  2014 May-Jun       Impact factor: 1.896

6.  Anti-Lipoarabinomannan-Specific Salivary IgA as Prognostic Marker for Leprosy Reactions in Patients and Cellular Immunity in Contacts.

Authors:  André Alan Nahas; Mayara Ingrid de Sousa Lima; Isabela Maria Bernardes Goulart; Luiz Ricardo Goulart
Journal:  Front Immunol       Date:  2018-05-30       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.